Glenmede Trust Co. NA Reduces Position in Kenvue Inc. $KVUE

Glenmede Trust Co. NA decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 11.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 401,685 shares of the company’s stock after selling 53,193 shares during the quarter. Glenmede Trust Co. NA’s holdings in Kenvue were worth $6,925,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Montag A & Associates Inc. raised its position in shares of Kenvue by 6.3% in the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after purchasing an additional 600 shares in the last quarter. Cornerstone Wealth Group LLC increased its stake in shares of Kenvue by 5.9% in the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. increased its stake in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Mill Creek Capital Advisors LLC raised its holdings in Kenvue by 0.6% in the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after acquiring an additional 701 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management raised its holdings in Kenvue by 0.3% in the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after acquiring an additional 712 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.98 on Tuesday. The company has a market cap of $36.45 billion, a P/E ratio of 22.34, a PEG ratio of 1.46 and a beta of 0.47. The business has a 50 day moving average of $18.62 and a two-hundred day moving average of $18.03. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.28. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.24 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s dividend payout ratio is 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.59% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. UBS Group increased their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen raised Kenvue to a “buy” rating in a report on Sunday, July 12th. Finally, Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.